Roche announced that it has entered into an agreement with PathAI in which the two companies will jointly develop an embedded image-analysis workflow for pathologists.
The workflow will allow PathAI's image-analysis algorithms to be accessed within NAVIFY Digital Pathology, the cloud version of Roche’s uPath enterprise software. Roche said pathologists will access Path AI's software through Roche’s Digital Pathology Open Environment.
This agreement with PathAI is among the first to expand digital tools through the Roche’s Digital Pathology Open Environment.
Roche will initially distribute Path AI-developed research-use-only (RUO) algorithms through NAVIFY Digital Pathology, spanning multiple cancer types. The combined innovation will expand support for healthcare companies’ companion diagnostic and drug development programs.
Roche offers two deployment options for its uPath software: an on-premise solution and a cloud solution, marketed as NAVIFY Digital Pathology. The VENTANA DP 200 slide scanner and Roche uPath enterprise software are CE-IVD marked for in-vitro diagnostic use and are available in the U.S. for research use only (RUO).
